Loading summary
Capital Group Host
In a world full of noise, long term thinking stands out. On the Capital Ideas podcast, Capital Group leaders explore the decisions that matter most in investing, leadership and life. It's a rare look inside a firm that's been helping people pursue their financial goals for more than 90 years. Listen to the Capital Ideas podcast from Capital Group, published by Capital Client Group Inc.
Luke Vargas
Will they talk or not? We'll get the latest on potential U S Iran diplomacy as the end of a 10 day ceasefire looms. Plus, with the world's focus elsewhere, North Korea speeds up work on its nuclear program and scientists close in on treatments to stop the genetic driver of lung cancer.
Xavier Martinez
It is so hard to target that researchers named it the Death Star. This weekend, researchers presented early results from two experimental drugs that their enthusiastic could work against it.
Luke Vargas
It's Monday, April 20th. I'm Luke Vargas for the Wall Street Journal and here is the AM edition of what's news, the top headlines and business stories moving your world today. After a three week long rally that has brought US Stocks to record highs, investors are once again bracing for uncertainty following a whirlwind of developments in the Iran war. Hopes had been raised last week for an end to the conflict and that the Strait of Hormuz was reopening to shipping traffic until Iran on Saturday said that the strait remained closed. In a series of social media posts yesterday, President Donald Trump called that a total violation of the ceasefire agreement and threatened to knock out all of Iran's bridges and power plants if Tehran doesn't agree to peace talks before the truce expires on Wednesday. Journal Middle east reporter Felice Solomon told us that expectations for a diplomatic breakthrough are beginning the week at a low point.
Felice Solomon
There's still a lot of uncertainty about how these talks are going to pan out. The two sides left the last round of talks very far apart on key issues, particularly Iran's future uranium enrichment, and that had actually been one of the key sticking points from the beginning. Right now, the US Is pushing for Iran to reopen the Strait of Hormuz for commercial shipping, freeze enrichment of uranium for at least 20 years, and agree to remove its stockpiles of enriched uranium if the talks happen. We'll see if Iran is willing to engage on some of these points. So far, it has signaled that it's not open to some of these demands. Iranian state media has said that they're excessive and considers Washington's blockade of the Strait of Hormuz to be a violation of the ceasefire.
Luke Vargas
Separately, the US Yesterday seized an Iranian ship that had attempted to get past its blockade of the Strait of Hormuz. The ship, which was previously sanctioned by the US and has frequently visited Chinese ports, was intercepted by an American destroyer after ignoring US Demands that it stop. Motor vessel Tosca. Motor vessel Tosca, vacate your engine room. Vacate your engine room. We're prepared to subject you to disabling fire. China's Foreign Ministry didn't immediately respond to a request for comment. Wary of the potential long term economic consequences of the war, the United Arab Emirates has asked the US about offering it a financial lifeline. We exclusively report that could include a currency swap line which would give the Emirates Central bank cheap access to dollars in order to prop up its currency or shore up its foreign reserves. Emirati haven't made a formal request yet, but we report that they have argued it was President Trump's idea to attack Iran and that should they run out of dollars, the country could be forced to use the Chinese yuan for oil sales, an implicit threat to the US Dollar, which enjoys near exclusive use in oil transactions. The UAE Central bank didn't respond to requests for comment and a Fed spokesperson declined to comment. Meanwhile, with the world's focus on Iran, North Korea has accelerated work on its nuclear weapons program. Are k Bureau chief Tim Martin is in Seoul. Tim, what's the news here? What have we missed?
Tim Martin
North Korea's been very busy. They've come near completion of a new facility at its main Yongbyon nuclear site. There's more activity from a 5 megawatt reactor, a reprocessing unit, a light water reactor. They're conducting missile tests left and right. They just did one over the weekend with cluster munitions. This is Kim Jong Un exploiting the moment. He has a nuclear bomb he's perceives to be under no threat of a regime overthrow. And the US Is not threatening to invade North Korea. In fact, President Trump has often spoken of his close relationship with Kim Jong Un. And Moscow and Beijing have given all types of political, economic and military protection to Pyongyang.
Luke Vargas
Tim, would it be fair to say that whereas maybe Iran is still in a vulnerable pre nuclear phase, North Korea is looking like it's basically crossed a threshold here and is now commanding respect from world powers?
Tim Martin
I think that's what world events show. Iran, on the precipice of a nuclear program has made it a target by the Trump administration. We can look at Venezuela, Cuba, other countries that have nothing amounting to a nuclear program, but have also made them vulnerable to intimidation and tactics. There are certainly international agencies that still raise alarm about North Korea's nuclear advances. In fact, Rafael Grossi, the UN's International Atomic Energy Agency chief, recently said, all this activity points to very serious increase in their capabilities. But what's the ability to stop, thwart, convince North Korea not to go down this nuclear pathway that has more or less been eliminated. The main historical mechanism to do this would have been at the United Nations. However, Russia and China have veto powers to any type of deepening or tightening of sanctions.
Luke Vargas
That was our Korea bureau chief, Tim Martin. And Japan is for the first time ever going to export its warships. Shares in Mitsubishi Heavy Industries are up more than 3% today after the company finalized a deal to supply frigates to the Royal Australian Navy. The more than $7 billion agreement comes as Japan prepares to loosen restrictions on exporting lethal weapons amid growing global demand for munitions and military equipment. And with oil prices now rallying again on concerns that the Iran war could drag out, the specter of rising inflation is back. Investors hunting for clues on the war's effect on the US Economy will have a lot to consider this week, starting with a retail sales update tomorrow that'll feel whether consumer spending has slowed as a result of rising prices. PMI readings for April, due on Thursday, will show the hit to the manufacturing and services sectors. And on Friday, it's the closely watched Consumer sentiment report from the University of Michigan. And amidst it all, the Trump administration is hoping to push through Kevin Warsh's nomination for Fed chair, with his Senate confirmation due to begin tomorrow. But as Telus Demos explained on WSJ's take on the Week podcast, that might not be so straightforward if Jerome Powell
Telus Demos
doesn't leave the Fed when his term ends, which is in the middle of May. There's kind of a race to officially confirm Warsh ahead of that. But there's this ongoing sort of issue with Senator Tillis, who's put a hold on the nomination until the Department of Justice drops its investigation of Jerome Powell. So a lot of drama about how quickly will Warsh's nomination actually move. And that's all before, like the substantive drama around Kevin Warsh, which is that he has argued that we can and should be cutting interest rates. And it's becoming harder arguably to make the case that we should be cutting rates in the face of the risk of an oil price shock, but also a really tough to read labor market.
Luke Vargas
Coming up, a pair of new drugs targeting a genetic driver of lung cancer show strong trial results. And Blue Origin misses the mark on an attempted satellite launch. Those stories after the break.
Schwab Representative
Trading at Schwab is now powered by Ameritrade, giving you even more specialized support than ever before. Like access to the trade desk. Our team of passionate traders ready to tackle anything from the most complex trading questions to a simple strategy. Gut check. Need assistance?
Xavier Martinez
No problem.
Schwab Representative
Get 24. 7 professional answers and live help and access support by phone, email and in platform chat. That's how Schwab is here for you to help you trade brilliantly. Learn more@schwab.com trading
Luke Vargas
we're exclusively reporting that Eli Lilly is in advanced talks to acquire Colonia Therapeutics for more than $2 billion, with a deal coming as soon as today if talks don't fall apart. Boston based Colonia is developing a next generation treatment for the blood cancer multiple myeloma. And buying the privately held company could help Eli Lilly to boost its position in the lucrative blood canc cancer segment of a global cancer drug market worth almost a quarter trillion dollars. Meanwhile, Journal News associate Xavier Martinez says that doctors may be getting closer to having a potent weapon against a genetic driver of lung cancer that's long lacked any targeted treatment options.
Xavier Martinez
Scientists have spent decades trying to crack a genetic mutation called kras. It drives some of the deadliest cancers, including lung cancer. But it is so hard to target that researchers named it the Death Star. This weekend at a major cancer conference in San Diego, researchers presented early results from two experimental drugs that their enthusiastic could work against it. In one study, a drug called Zoldan Rasib shrank lung cancer tumors in more than half of patients with a variant of the mutation that has never had a targeted treatment. In the other study, a drug called Elis Rasib shrank lung cancer tumors in nearly 60% of patients, roughly double the rate seen with existing approved drugs. It's still early. These are small trials and preliminary data, but doctors are saying that it could be a breakthrough for patients who have had very few options. That could be a very big deal.
Luke Vargas
And finally, it's time to put on my ear protectors, because Blue Origin yesterday celebrated the company's first commercial launch for its massive new Glenn rocket. The reusable rocket even nailed its landing.
Capital Group Host
Welcome back. Once again, never tell me the odds. It's good to say that, but a
Luke Vargas
satellite it was carrying wasn't deployed correctly, with Blue Origin saying in a social media post that the satellite, owned by AST Space Mobile, was deployed into an incorrect orbit. AST Space Mobile is building a cellular broadband network in space, but said the satellite's altitude was too low to sustain operations and that it will be taken out of orbit. The stumble comes as Jeff Bezos. Blue Origin works to ramp flights to address a backlog and better challenge Elon Musk's SpaceX, which has a dominant position in the launch market. And that's it for what's news for this Monday morning. Today's show was produced by Daniel Bock and Hattie Moyer. Our supervising producer is Sandra Kilhoff, and I'm Luke Vargas for the Wall Street Journal. We will be back tonight with a new show, and until then, thanks for listening.
Capital Group Host
Your next chapter in healthcare starts at Carrington College's School of Nursing in Portland. Join us for our open house on Tuesday, January 13th from 4 to 7pm you'll tour our campus, see live demos, meet instructors and learn about our associate degree in Nursing program that prepares you to become a registered nurse. Take the first step toward your nursing career. Save your spot now at Carrington. Edu Events. For information on program outcomes, visit carrington. Edu Sci Fi.
Date: April 20, 2026
Host: Luke Vargas
Guests/Reporters: Felice Solomon, Tim Martin, Xavier Martinez, Telus Demos
This episode covers critical developments in geopolitics and global markets, focusing on the looming end of a ceasefire between the US and Iran, the rapid nuclear advancements in North Korea while global attention is fixed elsewhere, new breakthroughs in cancer treatments, and updates on the commercial space race. The episode maintains a brisk, informative tone, providing listeners with context and implications for business, finance, and politics.
Background (00:33–01:58):
Felice Solomon, Middle East Reporter (01:58–02:39):
US Seizes Iranian Ship (02:39–04:09):
Tim Martin, Korea Bureau Chief (04:09–05:53):
Strategic Contrast With Iran (05:01–05:53):
Japan’s New Arms Exports (05:53–06:23):
Economic Impact of Oil and War (06:23–07:08):
Federal Reserve Drama (07:08–07:56):
Experimental Lung Cancer Drugs (09:22–10:14):
Pharma Moves (08:43–09:22):
Blue Origin Launch (10:14–10:33):
Deployment Failure (10:33–10:54):
Felice Solomon (01:58):
“There’s still a lot of uncertainty about how these talks are going to pan out...the two sides left the last round of talks very far apart on key issues, particularly Iran’s future uranium enrichment, and that had actually been one of the key sticking points from the beginning.”
Tim Martin (04:09):
“This is Kim Jong Un exploiting the moment. He has a nuclear bomb...He perceives to be under no threat of a regime overthrow. And the US is not threatening to invade North Korea.”
Xavier Martinez (09:22):
“Scientists have spent decades trying to crack a genetic mutation called kras...it is so hard to target that researchers named it the Death Star.”
Telus Demos (07:08):
“There’s kind of a race to officially confirm Warsh ahead of that. But there’s this ongoing sort of issue with Senator Tillis, who’s put a hold on the nomination until the Department of Justice drops its investigation of Jerome Powell.”
The discussion is brisk, fact-driven, and urgent, matching the stakes in global geopolitics and the business context dominating the week. The episode balances complex political analysis with concise market updates and scientific breakthroughs, never losing sight of the listener's need for clarity on what will move markets and global events.
Ideal for listeners seeking an efficient, high-impact briefing on global affairs, market movements, and headline scientific announcements—this episode of What's News delivers the news that matters, with expert insight and razor-sharp analysis.